Abstract
Background
Information regarding characteristics and risk factors of COVID-19 amongst middle-aged (40–59 years) patients without comorbidities is scarce.
Methods
We therefore conducted this multicentre retrospective study and collected data of middle-aged COVID-19 patients without comorbidities at admission from three designated hospitals in China.
Results
Among 119 middle-aged patients without comorbidities, 18 (15.1%) developed into severe illness and 5 (3.9%) died in hospital. ARDS (26, 21.8%) and elevated D-dimer (36, 31.3%) were the most common complications, while other organ complications were relatively rare. Multivariable regression showed increasing odds of severe illness associated with neutrophil to lymphocyte ratio (NLR, OR, 11.238; 95% CI 1.110–1.382; p < 0.001) and D-dimer greater than 1 µg/ml (OR, 16.079; 95% CI 3.162–81.775; p = 0.001) on admission. The AUCs for the NLR, D-dimer greater than 1 µg/ml and combined NLR and D-dimer index were 0.862 (95% CI, 0.751–0.973), 0.800 (95% CI 0.684–0.915) and 0.916 (95% CI, 0.855–0.977), respectively. SOFA yielded an AUC of 0.750 (95% CI 0.602–0.987). There was significant difference in the AUC between SOFA and combined index (z = 2.574, p = 0.010).
Conclusions
More attention should be paid to the monitoring and early treatment of respiratory and coagulation abnormalities in middle-aged COVID-19 patients without comorbidities. In addition, the combined NLR and D-dimer higher than 1 μg/ml index might be a potential and reliable predictor for the incidence of severe illness in this specific patient with COVID-19, which could guide clinicians on early classification and management of patients, thereby relieving the shortage of medical resource. However, it is warranted to validate the reliability of the predictor in larger sample COVID-19 patients.
Similar content being viewed by others
Background
The novel coronavirus disease 2019 (COVID-19) pandemic has posed a great health threat globally. As of June 16, 2020, according to the latest situation report from WHO, the SARS-CoV-2 has infected 7,823,289 people around the world and caused 431,541 deaths [1]. The population is generally susceptible to the SARS-CoV-2. Unfortunately, much of the pathogenesis and optimal therapy of COVID-19 remains unclear.
Rapidly accumulating evidences have shown the risk factors for severe illness and death in COVID-19. Based on current studies, older age has been identified to be associated with an increased risk of death in COVID-19, as well as comorbidities [
The complications and outcomes of middle-aged (40–59 years) COVID-19 patients without comorbidities
Among the 119 patients who were discharged or died at the study end point, 11 (9.24%) were treated in the ICU, 18 (15.1%) received mechanical ventilation, 2 (1.68%) were treated with continuous renal replacement therapy, and 5 (4.2%) died (Table 3). ARDS (26, 21.8%) was the most common complications, followed by acute liver injury (16, 13.4%), septic shock (5, 4.3%), acute cardiac injury (4, 3.4%) and acute kidney injury (3, 2.5%). Severe patients yielded significantly higher rates of any complication as compared with non-severe patients. The median time from symptom onset to ARDS in severe and non-severe patients was 8 days (IQR, 7–12) and 10 days (IQR, 8–11), respectively. The median time from symptom onset to other complications was all about 2 weeks. Mortality rate in severe patients was 27.8%, while there was no death in the non-severe patients. The general characteristics and cause of death of 5 non-survived COVID-19 middle-aged patients without comorbidities were shown in Table 4. Severe ARDS was the main cause of death.
Risk factors for severe COVID-19 of middle-aged patients without comorbidities
The results of univariate and multivariate logistic regression models assessing the relations between variables on admission and the development of severe COVID-19 were shown in Table 5. In univariable analysis, high fever, dyspnea, leucocytosis, lymphopenia, elevated NLR, lactate dehydrogenase, hypoalbuminemia, D-dimer greater than 1 μg/ml and higher SOFA score at admission were associated with the development of severe COVID-19. Additionally, multivariate logistic regression analysis revealed that the higher NLR (OR, 1.238, 95% CI 1.110–1.382, p < 0.001) and D-dimer greater than 1 μg/ml (OR, 16.079, 95%CI, 3.162–81.775, p = 0.001) on admission were the independent risk factors for the development of severe COVID-19 (Table 5).
Predictive performance of the NLR, D-dimer and combined index for the development of severe COVID-19
ROC curve analysis was used to analyze the predictive performance of the NLR, D-dimer and combined NLR and D-dimer (Fig. 2). As recent publications demonstrated that SOFA could well predict the severity and outcome of COVID-19, we compared the predictive performance of these risk factors and SOFA for the development of severe COVID-19 in middle-aged patients without underlying disease. The optimal cut-offs and corresponding sensitivity and specificity and AUC were listed in Table 6. The optimal cut-off value of NLR for predicting severe illness was 5.03, which yielded sensitivity and specificity of 88.2% and 66.2%, respectively. The optimal cut-off value of SOFA was 2, which resulted in sensitivity and specificity values of 70.6% and 70.4%, respectively. SOFA and NLR yielded an AUC of 0.750 (95% CI 0.602–0.987) and 0.862 (95% CI 0.751–0.973), respectively. However, there was no significant difference in the AUC between SOFA and NLR (Z = 1.325, p = 0.185). We further combined NLR and D-dimer higher than 1 μg/ml to draw another ROC curve, as shown in Fig. 2, yielding much greater discriminatory capacity for severe illness, with an AUC of 0.916 (95% CI 0.855–0.977). The Delong’s test showed that there was significant difference in the AUC between SOFA and combined index (z = 2.574, p = 0.010). These results demonstrated the prediction effect of the combined index was significantly better than that of SOFA.
ROC curve analysis using the NLR, D-dimer, combined index and SOFA for predicting severe COVID-19 in middle-aged (40–59 years) patients without comorbidities. COVID-19 coronavirus disease 2019, AUC area under the curve, CI confidence interval, NLR neutrophil to lymphocyte ratio, SOFA Sequential Organ Failure Assessment, Combined index combined NLR and D-dimer > 1 μg/ml index
Discussion
To our knowledge, the present study is the first multicentre study to investigate the clinical characteristics, risk factors and predictors for severe illness in middle-aged COVID-19 patients without comorbidities. In this retrospective cohort study, the incidence of severe COVID-19 in middle-aged patients without comorbidities was significantly lower than that in elderly patients (15.1% vs. 57.1%) while higher than that in young patients (15.1% vs. 2.6%). In addition, the incidence of complications in this specific population was lower than that in general population except for ARDS and acute liver injury. We also found that elevated NLR and D-dimer levels on admission were risk factors for the development of severe COVID-19. In particular, the combination of NLR and D-dimer levels higher than 1 μg/ml had a good predictive value for severe COVID-19 in this specific population, even better than SOFA score.
In the middle-aged COVID-19 patients without comorbidities in this study, patients with high fever, dyspnea, elevated levels of NLR, LDH and D-dimer, as well as decreased ALB in early stage were more common in severe COVID-19. Compared to the overall COVID-19 patients (Additional file 1: Table S2), the proportion of severe cases, as well as the incidence of sepsis shock, acute cardiac injury, and other organ injury complications were lower in middle-aged COVID-19 patients. There was no difference in the incidence of acute liver injury between the two groups. Similar to previous studies, the prevalence of abnormal liver function tests (LFTs) was high in COVID-19 patients, whereas acute liver injury was usually mild, with limited clinical relevance and no treatment required [19,20,21].
Extensive studies have suggested that COVID-19 patients with any comorbidity were more likely to develop severe organ injury related to pre-existing diseases. A retrospective cohort study of 3,069 hospitalized patients with COVID-19 in US demonstrated that patients with cardiovascular disease (CVD) were more likely to have myocardial injury than patients without CVD (73.2% vs. 19.3%) [22]. Similarly, compared with COVID-19 patients without chronic obstructive pulmonary disease (COPD), patients with COPD were more likely to develop pulmonary bacterial or fungal coinfection (20.0% vs.5.9%), ARDS (20.0% vs. 7.3%), and septic shock (14.0% vs. 2.3%) [31,32]. Consistent with our results, in a meta-analysis of 5 studies from China with 828 patients, NLR was found to increase significantly in patients with severe diseases (standardized mean difference = 2.404, 95% CI 0.98–3.82) [33]. Besides COVID-19, the increased NLR has been shown to have strong association with the severity of many other diseases, including septic shock [34], tumor [35], and bacterial infection [36]. Moreover, numerous studies have shown that the hypercoagulable state induced by COVID-19 was associated with poor outcomes of patients [2, 37, 38]. Consistent with these recent studies, we found in this study that D-dimer higher than 1 μg/ml on admission was as much as 16.079 times (95% CI 3.162–81.775) more likely to develop severe COVID-19 than those with D-dimer lower than 1 μg/ml. In a recent meta-analysis, Wu, et al. demonstrated that higher C reaction protein (CRP) levels were commonly observed in COVID-19 patients who developed thromboembolic events, and the thromboembolic events were also associated with adverse outcomes [27]. The association between acute inflammation and thromboembolic events has been indicated by numerous studies [26, 28, 29]. In addition, endothelial activation or dysfunction, and complement activation might be all involved in the hypercoagulable state in COVID-19 [39, 40].
We also found in our study that the combined NLR and D-dimer index was a good prognostic biomarker for the development of severe COVID-19, even better than SOFA score. Our results showed that NLR alone yielded a relatively high AUC (0.862, 95% CI 0.751–0.973) to predict the development of severe COVID-19, while the specificity was just 66.2%. The combined use of D-dimer and NLR not only yielded a significantly elevated AUC of 0.916 (95% CI 0.855–0.977; p < 0.001), but also resulted in a greatly increased specificity from 66.2% to 82.7%. The SOFA score was a morbidity severity score and was originally designed to focus on organ dysfunction and morbidity [41]. Increasing evidences have suggested that SOFA score could well predict the severity and outcome of the disease [42, 43], including sepsis, septic shock [12], as well as COVID-19 [2]. In this study, although SOFA yielded a AUC (0.750, 95% CI 0.602–0.987) with 70.6% sensitivity and 70.4% specificity, the statistical results indicated that the combined index was significantly better than SOFA for predicting the incidence of severe illness in COVID-19 (z = 2.574, p = 0.010). In addition, compared with the overall patient population, the prediction for severe COVID-19 by this combined index showed higher sensitivity (82.4%) and specificity (82.7%) in middle-aged patients without comorbidities. In a study of 96 patients, Yang, et al. demonstrated that the optimal cut-off value of NLR for predicting severe COVID-19 was 3.3, which yielded sensitivity and specificity of 63.6% and 88.0%, respectively [44]. Similarly, in another analysis of 301 patients, a NLR at 2.973 was associated with the progression of COVID-19, which only yielded an AUC of 0.734, with sensitivity and specificity of 75.8% and 66.8%, respectively [45]. Most importantly, compared with SOFA score consisting of 6 variables, NLR and D-dimer could be obtained much easier and quicker by routine hematology. Therefore, combined NLR and D-dimer index might be an easy-to-use and reliable predictor for the severity of the middle-aged COVID-19 patients without comorbidities. Remarkably, many other prognostic factors are widely investigated in patients with COVID-19, such as CRP and other inflammatory biomarkers which correlates to disease severity. Recently a systematic review and a meta-analysis enhanced these data in COVID-19 patients. Izcovich, et al. included 207 studies and found high or moderate certainly that 49 variables, including high interleukin-6 (IL-6), high blood lactate dehydrogenase (LDH) and many other indicators, could provide valuable prognostic information on mortality and/or severe disease in COVID-19 [46]. In addition, in a meta-analysis of 5350 COVID-19 patients from 25 studies, Huang, et al. concluded that an elevated serum CRP, procalcitonin, D-dimer, and ferritin were associated with a poor outcome in COVID-19 [47]. Therefore, in the face of more and more COVID-19 related risk factors, how to select the most effective and convenient predictors in specific populations still need more research.
Our study has some limitations. First, due to the retrospective study design, not all laboratory tests were done for all patients, especially the detection of immune related indicators. Although lymphocyte count could partly reflect the suppression of immune function, there was still a lack of comprehensive understanding of the patient's immune status. Second, the past history was provided by the patients or their relatives. Some patients might have unknown comorbidities due to the lack of previous basic medical data. However, these patients had a high self-awareness rate of hypertension, diabetes and other common diseases, owing to most of them came from cities and towns and received regular screening for common diseases. Third, as a multicentre study, the data in the study were from three different hospitals, which might lead to differences in testing results. However, the data in this study were all clinical routine test items. With the continuous promotion of external quality evaluation and standardization of clinical laboratory, the routine test items in most hospitals in China had reached a high degree of standardization.
Conclusions
In summary, our study revealed that the lung and coagulation system suffered the most serious attack by SARS-CoV-2 in middle-aged COVID-19 patients without comorbidities while other organs were less damaged. More attention should be paid to the monitoring and early treatment of respiratory and coagulation abnormalities in this specific population. In addition, the combined NLR and D-dimer higher than 1 μg/ml index might be a potential and reliable predictor for the incidence of severe illness in this specific patient with COVID-19, which could guide clinicians on early classification and management of patients, thereby relieving the shortage of medical resource. However, it is warranted to validate the reliability of the predictor in larger sample COVID-19 patients.
